Elacridar (GF120918) is a potent dual inhibitor of P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) — the two dominant efflux transporters at the intestinal wall and blood-brain barrier (BBB). Its therapeutic promise has been validated in multiple Phase I trials, but its development stalled because of dissolution-rate-limited oral bioavailability. Our proprietary microemulsion/nanoformulation resolves this constraint, creating a valuable co-formulation tool. Eli Lilly's oncology portfolio is uniquely well-positioned for elacridar combinations: the majority of Lilly's approved small-molecule cancer drugs are P-gp and/or BCRP substrates, and several face the specific clinical challenge of inadequate CNS penetration — the single biggest unmet need in solid tumour oncology. The combination of Verzenio (abemaciclib) + bioavailable elacridar for brain metastases from HR+/HER2− breast cancer represents our highest-conviction lead programme.
Mechanistic Foundation
Intestinal Absorption Enhancement
P-gp and BCRP expressed on intestinal epithelial brush border efflux substrate drugs back into the gut lumen, reducing oral bioavailability. Elacridar inhibits this efflux, increasing systemic AUC by 2–10× for susceptible drugs, enabling lower oral doses with equivalent or superior exposure.
Blood-Brain Barrier Penetration
At the BBB, P-gp and BCRP in cerebral capillary endothelium actively pump substrate drugs back into systemic circulation. For oncology drugs targeting CNS disease, this mechanism can reduce brain drug levels to sub-therapeutic concentrations. Elacridar co-administration can increase brain penetration by 3–60-fold in preclinical models.
Multidrug Resistance Reversal
Tumour cells upregulate P-gp and BCRP as a primary resistance mechanism. Elacridar can partially restore chemosensitivity in resistant tumours. Validated in CML (imatinib resistance) and breast cancer cell lines — offers a route to extend drug utility beyond initial LOE cliff.
The Bioavailability Problem — Solved
Elacridar's poor aqueous solubility (BCS Class IV) historically limited oral use. Our bioavailable formulation (microemulsion/lipid nanoparticle) achieves systemic exposure sufficient to inhibit BBB and intestinal transporters at well-tolerated doses, enabling chronic oral co-dosing — the key commercial enabler.
Lilly Portfolio × Elacridar: Combination Assessment
All currently marketed Lilly oncology and neuroscience drugs assessed for P-gp/BCRP substrate status and combination opportunity. Financials reflect FY2024 data where available.
| Drug / Brand | Class / Indication | P-gp/BCRP Status | Elacridar Benefit Type | FY2024 Sales | Projected Peak Sales (Combination) | LOE | Priority |
|---|---|---|---|---|---|---|---|
|
Abemaciclib
Verzenio®
|
CDK4/6 inhibitor HR+/HER2− breast cancer (adjuvant + metastatic) |
Confirmed dual substrate (ABCB1 + mAbcg2). Brain penetration increased 25–60-fold in P-gp/BCRP knockout mice. Active metabolites M2/M20 even more restricted. |
↑ CNS Efficacy ↓ Dose (Peripheral) |
$5.28B (2024 worldwide) |
$7.5–9.0B brain mets indication adds $1.5–2.5B incremental |
~2033 (composition patents) |
★ Priority 1 |
|
Selpercatinib
Retevmo®
|
RET inhibitor RET+ NSCLC, thyroid cancer, solid tumours |
Confirmed ABCB1 + mAbcg2 substrate. Elacridar boosts brain penetration to knockout-mouse levels (6.2× in combined knockout). 46% of RET+ NSCLC patients develop brain mets. |
↑ CNS Efficacy ↓ Systemic Dose |
~$320M (FY2024 est.) |
$1.0–1.5B dedicated CNS indication |
~2035 (RET inhibitor patents) |
Priority 2 |
|
Pirtobrutinib
Jaypirca®
|
Non-covalent BTK inhibitor MCL, CLL/SLL (post-covalent BTKi) |
Acts as P-gp and BCRP inhibitor itself (not substrate). Limited direct BBB benefit. However, limited CNS lymphoma data exists; CNS relapse in CLL/MCL is a clinical challenge. | Limited Synergy | ~$385M (FY2024) |
$600–800M marginal uplift at best |
~2036 | Low |
|
Donanemab
Kisunla™
|
Anti-amyloid mAb Early symptomatic Alzheimer's disease |
Biologic — not a P-gp/BCRP substrate. Monoclonal antibodies have distinct BBB access mechanisms (transcytosis, FcRn). Elacridar irrelevant for mAb CNS delivery. | Not Applicable | ~$30M (2024, early launch) |
N/A | ~2036 | N/A |
|
Ramucirumab
Cyramza®
|
Anti-VEGFR-2 mAb Gastric, NSCLC, CRC, HCC |
Biologic — not applicable. IV-administered; elacridar combination adds no meaningful pharmacokinetic value. | Not Applicable | ~$600M (FY2024 est.) |
N/A | ~2027–2029 | N/A |
|
Imlunestrant
Pipeline — Phase 3
|
Oral SERD (ER degrader) ER+/HER2− metastatic breast cancer |
Oral SERD; likely ABCB1/ABCG2 substrate given chemical class. Brain mets in ER+ MBC highly prevalent. ESR1-mutant tumours developing in CNS sanctuary is a major unmet need. Data still emerging. |
Probable CNS Benefit Potential Dose Reduction |
Not yet launched | $2.5–4.0B + combination premium $500M–1B |
~2037–2040 | Priority 2 (Pipeline) |
|
Olomorasib
Pipeline — Phase 3
|
KRAS G12C inhibitor NSCLC, CRC (post-sotorasib/adagrasib) |
Small-molecule KRAS inhibitor; likely P-gp substrate (structural homology with other KRAS inhibitors). Brain mets in KRAS+ NSCLC are emerging clinical challenge. Worth profiling. | Possible CNS Benefit | Not yet launched | $1.5–2.5B + possible combination uplift |
~2038+ | Priority 3 |
Deep Dive: Top Combination Opportunities
Combination #1: Abemaciclib + Bioavailable Elacridar
Scientific Rationale: Abemaciclib and its pharmacologically active metabolites (M2, M20, M18) are confirmed substrates of both ABCB1 (P-gp) and ABCG2 (BCRP). In knockout mouse models, combined ABCB1/ABCG2 deficiency increased relative brain penetration of the parent compound by 25-fold and M20 by an extraordinary 60-fold. This indicates that at the BBB, elacridar could achieve a dramatic and clinically meaningful increase in CNS drug levels.
Clinical Context: Brain metastases (BM) occur in 10–30% of patients with HR+/HER2− metastatic breast cancer. Despite Verzenio's some inherent BBB penetration (CSF levels observed in Phase 1 glioblastoma studies), the Phase 2 BCBM trial (NCT02308020) showed a modest intracranial ORR of only 6% — dramatically below systemic efficacy. This is the clinical signal that elacridar can directly address. Elacridar co-administration would be expected to increase brain drug levels by a magnitude that could shift intracranial ORR into the 25–40% range — a clinically transformative improvement.
Commercial Logic: BCBM represents an indication with no approved CDK4/6 inhibitor. A combination product obtaining its own regulatory approval for BCBM creates a new, independently patentable indication that extends commercial exclusivity meaningfully beyond Verzenio's ~2033 LOE. Given the $5.28B base, even a 10–15% price premium for a combination product capturing the BCBM sub-population would generate $500M–$1.5B of incremental annual revenue. The combination could also partially defend the core metastatic BC franchise against generic abemaciclib by offering superior outcomes through better CNS control.
Dose Reduction Opportunity: ABCB1/ABCG2 efflux also limits systemic exposure of abemaciclib metabolites. Elacridar co-administration could allow meaningful systemic dose reduction (potentially 25–40%) while maintaining equivalent tumour AUC — directly reducing grade 3/4 diarrhoea (the key dose-limiting toxicity), which currently affects ~10–20% of patients at the 150mg BID dose. A safer, better-tolerated combination at a lower dose with superior CNS penetration is a genuinely differentiated product profile.
Combination #2: Selpercatinib + Bioavailable Elacridar
Scientific Rationale: Selpercatinib is efficiently transported by hABCB1 (P-gp) and mAbcg2. In vivo, brain penetration increased 6.2-fold in combined ABCB1/ABCG2 knockout mice — and, critically, elacridar co-administration in wild-type mice fully replicated the knockout phenotype, demonstrating near-complete reversal of BBB efflux. CYP3A4 also limits selpercatinib oral exposure, and while elacridar is not a CYP3A4 inhibitor, the ABCB1/ABCG2 inhibition alone substantially increases CNS drug levels without any systemic dose escalation.
Clinical Context: Up to 46% of RET-fusion+ NSCLC patients develop brain metastases during their disease course. Selpercatinib showed intracranial response in Phase 1/2 (91% iORR in measurable CNS lesions), but the mechanistic data showing intrinsically poor BBB penetration in wild-type animals suggests this clinical activity is sub-maximal and at significant risk of CNS progression as the primary resistance site. An elacridar combination could both deepen initial CNS responses and delay CNS-only progression — extending PFS significantly in the ≈46% of patients who will develop or have BM.
Commercial Logic: While Retevmo is a smaller product today (~$320M), RET-targeted therapy is still in early market development. A combination product capturing the CNS-metastatic NSCLC sub-population (an enormously underserved segment) could be the basis for a first-in-class "BBB-penetrant RET inhibitor combination" approval, potentially tripling the drug's addressable market.
Combination #3: Imlunestrant + Bioavailable Elacridar
Scientific Rationale: Oral SERDs as a class are lipophilic small molecules that are known or suspected ABCB1/ABCG2 substrates (the approved oral SERD elacestrant, structurally related, shows P-gp substrate behaviour). ESR1 mutations — the primary driver of imlunestrant's patient selection — frequently arise under the selective pressure of endocrine therapy in CNS metastases, creating a CNS sanctuary site. Elacridar co-administration could address this by enhancing brain penetration of imlunestrant in the ESR1-mutant sub-population.
Strategic Timing: The combination of imlunestrant + abemaciclib is already showing strong data (EMBER-3). A triple approach — imlunestrant + abemaciclib + elacridar — targeting the BCBM population would be a logical Phase 2 study leveraging our platform. This creates a potential franchise play across Lilly's entire HR+ breast cancer portfolio.
Key Risk: Imlunestrant is not yet approved; P-gp/BCRP substrate status needs formal confirmation. This remains a high-upside watch closely as data emerge.
Pipeline Watch — Olomorasib (KRAS G12C) + Elacridar
Lilly's Phase 3 KRAS G12C inhibitor olomorasib is structurally analogous to AMG-510 (sotorasib) and MRTX-849 (adagrasib). Adagrasib has documented brain penetration issues in preclinical models linked to P-gp efflux, and elacridar combinations have been explored in CNS preclinical models for this compound class. If olomorasib is confirmed as a P-gp/BCRP substrate — which should be established before IND — a combination play targeting NSCLC with brain metastases (>25% of KRAS G12C patients at diagnosis) becomes viable. Recommend formal transporter substrate profiling as part of due diligence within 6 months.
Abemaciclib + Bioavailable Elacridar
for Breast Cancer Brain Metastases
Why this combination is our lead:
- 01. Strongest preclinical signal in the portfolio. The 25–60-fold increase in brain penetration of abemaciclib and its metabolites in ABCB1/ABCG2 knockout models is among the most compelling transporter-driven CNS data for any approved oncology drug. This magnitude of effect, when reproduced by elacridar, is clinically transformative — not merely incremental.
- 02. Validated clinical unmet need with existing Phase 2 signal. The BCBM Phase 2 trial (NCT02308020) confirmed abemaciclib enters the CNS and has biological activity, but demonstrated an inadequate 6% intracranial ORR — exactly the profile of a drug whose CNS activity is transporter-limited. This creates a clean mechanistic hypothesis for our Phase 1b/2 combination trial.
- 03. Largest addressable revenue base. Verzenio's $5.28B (FY2024) and $5.7B (FY2025) base means even modest combination premium capture on the BCBM indication generates $500M–$1.5B+ of incremental commercial value. No other Lilly oncology drug offers this scale.
- 04. IP lifecycle extension. A novel combination product targeting BCBM creates independently patentable claims (combination, method-of-use, formulation), extending effective commercial exclusivity to 2038–2040, well beyond abemaciclib's core LOE of ~2033. This is the clearest lifecycle management play in Lilly's portfolio.
- 05. Dual benefit: CNS efficacy AND improved tolerability. The combination simultaneously improves CNS outcomes AND enables systemic dose reduction (addressing grade 3/4 diarrhoea, the primary Verzenio quality-of-life limitation). This dual value proposition is compelling for physicians and payers, and differentiated from single-mechanism improvements.
- 06. Regulatory pathway clarity. Elacridar has a well-characterised safety profile from Phase I combination trials (topotecan, doxorubicin). A focused Phase 1b dose-finding study in BCBM patients with measurable intracranial disease, followed by a randomised Phase 2/3 vs. abemaciclib alone, is a clearly precedented, FDA-acceptable development plan.
- 07. Lilly strategic alignment. Lilly has already invested heavily in the monarchE, MONARCH-2, and MONARCH-3 franchise. They have existing Verzenio-specific KOL relationships, commercial infrastructure, and are actively advancing imlunestrant + abemaciclib combinations. Our BCBM play is complementary and fills a gap they have not pursued — making a co-development or licensing deal with Lilly itself a credible and attractive outcome.
The proposed development plan: Phase 1b (dose-finding, PK/PD, CSF sampling) in BCBM patients on background abemaciclib → Phase 2 (randomised, open-label) vs. abemaciclib monotherapy in HR+/HER2− BCBM → sBLA submission for the combination in BCBM. Target IND submission within 18 months of formulation lock. Total development investment estimated $80–120M to Phase 2 proof of concept.
Risk & Opportunity Assessment — Lead Programme
Key Opportunities
- First approved therapy specifically for BCBM from this drug class
- Clean mechanistic rationale — not a shot in the dark
- Elacridar safety profile already characterised in Phase I
- Bioavailable formulation is the novel IP — low risk of Lilly competition
- Natural Lilly licensing/partnership target at Phase 2 proof of concept
- Extends Verzenio exclusivity beyond LOE cliff
- Dual safety + efficacy narrative for payers
- CSF PK endpoint offers clear early PD readout before Phase 3
Key Risks & Mitigations
- CYP3A4 DDI risk: Abemaciclib is CYP3A4-metabolised; elacridar is not a CYP3A4 inhibitor, limiting systemic DDI. Monitor carefully but risk is manageable.
- Elacridar CNS distribution: Elacridar itself is a P-gp substrate — requires adequate formulation dose to achieve sustained BBB inhibition. Our bioavailable formulation addresses this directly.
- Lilly could develop own P-gp inhibitor: Risk partially mitigated by our IP on the bioavailable formulation and combination method-of-use patents.
- Small BCBM patient numbers for pivotal trial: Enriched population design and adaptive trial methodology can address statistical power concerns.
- Payer reimbursement for combo: Dual-agent combination pricing requires robust health-economic modelling showing survival benefit in BCBM sub-population.
Compounds Deprioritised — Rationale
Several Lilly products were assessed and deprioritised: Kisunla (donanemab) and Cyramza (ramucirumab) are biologics, making P-gp/BCRP-based combination strategies mechanistically irrelevant. Jaypirca (pirtobrutinib) is itself a P-gp/BCRP inhibitor rather than substrate, providing no PK benefit from elacridar co-administration; and CNS lymphoma in CLL/MCL is a rare event managed differently than solid tumour brain metastases. Mounjaro/Zepbound (tirzepatide) and metabolic/immunology drugs (Taltz, Omvoh, Ebglyss) are injectable biologics or drugs operating outside tissues where P-gp/BCRP efflux is clinically rate-limiting. Trulicity (dulaglutide) is a GLP-1 agonist/biologic — not applicable. None of these represent viable or rational elacridar combination targets.